407 results on '"N Di Muzio"'
Search Results
102. Application of failure mode and effect analysis to tomotherapy treatment delivery
103. 63. Quantification of skin dose changes during Tomotherapy for head-neck cancer by dose-of-the-day recalculation
104. 46. Skin DVHs predict cutaneous toxicity in head and neck cancer patients treated with radiochemotherapy
105. 237. Robustness of FDG-PET radiomic features against tumor delineation in two clinical relevant scenarios
106. Comparing stereotactic body radiotherapy and elective nodal radiotherapy in the management of nodal oligorecurrent prostate cancer: a multi-institutional analysis
107. EP-1872: Stepping validation of a KB-model for plan optimization of prostatic/pelvic patients irradiation
108. EP-1191: Outcomes of a mono-institutional experience of IG-IMRT in Glioblastoma
109. EP-1990: Skin DVHs predict cutaneous toxicity in Head and Neck cancer patients treated with Tomotherapy
110. PO-0976: Rectal cancer radiochemotherapy: pathological response predicted by modeling early tumor regression
111. PO-0825: Urinary calprotectin as a promising biomarker of RT-induced urinary toxicity. Preliminary results
112. Factors affecting self-reported, long-term (1-2 yrs) urinary incontinence from postprostatectomy RT
113. The prognostic role of early PSA response after salvage radiation therapy: Long-term results from a multi-institutional study
114. What is the optimal field of post-prostatectomy radiation therapy? Long-term results from a multi-institutional study
115. Assessing the impact and predictors of other-cause mortality in patients treated with post-prostatectomy salvage radiation therapy in order to avoid possible overtreatment: Results from a large, multi-institutional study
116. EP-1459 Impact of sentinel lymph-node biopsy and FDG-PET in staging and radiation treatment of anal cancer
117. EP-1993 Evidence of CTV underdosing due to anatomical changes during breast Helical Tomotherapy
118. OC-0611 Planned and delivered DVHs of the skin predict acute cutaneous toxicity after IGRT for HN cancer
119. Validation of a method for 'dose of the day' calculation in head-neck tomotherapy by using planning ct-to-MVCT deformable image registration
120. Urinary calprotectin as a promising bio-marker of radiation-induced urinary toxicity and worsening of urinary function. Preliminary results
121. EP-1315: Prostate cancer lymph nodal disease: SBRT only or extensive prophylactic irradiation and boost?
122. PO-0730: The independent benefit deriving from high doses and WPRT in salvage post-prostatectomy radiotherapy
123. PO-0694: Post-operative Intensity-Modulated hypofractionated Image-Guided Radiotherapy in cholangiocarcinoma
124. EP-1319: 'Adjuvant'/ radical radiotherapy in prostate cancer patients with synchronous bone oligometastasis
125. EP-1318: Is hypofractionation combined to WPRT effective in high risk prostate cancer patients?
126. EP-1815: Technical aspects and setup irradiation of rats using a clinical accelerator
127. PO-0852: External validation of a TCP model predicting PSA relapse after post-prostatectomy Radiotherapy
128. External validation of a TCP model predicting PSA relapse after post-prostatectomy radiotherapy
129. An automatic contour propagation method to follow parotid gland deformation during head-and-neck cancer tomotherapy
130. 26. Stepping validation of 'knowledge-based' models for semi-automatic plan optimization: The case of concomitant treatment of pelvic nodes and prostatic bed in post-prostatectomy radiotherapy
131. 88. Integration of MR-tractography into radiation treatment planning for high-grade glioma
132. EP-1449: Neoadjuvant chemoradiotherapy IG-IMRT PET based in esophageal or esophageal gastric junction cancer
133. EP-1221: Hypoxia imaging with 18F-FAZA PET/CT in Radiotherapy Planning for High Grade Gliomas
134. EP-1390: Salvage (postponed) hypofractionated tomotherapy for progressive MPM in patients with intact lungs
135. Assessing the need for and the optimal duration of hormonal therapy in association with post-prostatectomy radiation therapy: Results from a multi-institutional study
136. Quality indicators in the intensity modulated/image-guided radiotherapy era
137. EP-1157 FDG-PET guided dose escalation with TomoTherapy for locally advanced oropharyngeal cancer
138. PD-0530: Predictors of hematological toxicity after whole-pelvis intensity-modulated post-prostatectomy radiotherapy
139. EP-1627: Inter-observer variability of intestinal loops delineation after whole pelvis radiotherapy for prostate patients
140. PO-1087 Gastrointestinal toxicity in post-prostatectomy pelvis irradiation: intestinal loops and sigmoid colon contouring
141. PO-0749: Factors predicting late severe urinary incontinence after postprostatectomy RT: a longitudinal study
142. EP-1347: Could 'radical' RT be a reasonable choice in bone oligometastatic prostate cancer patients?
143. EP-1300: Preoperative, Adaptive Radiotherapy with Tomotherapy concomitant with chemotherapy in rectal cancer
144. PO-0721: Impact of sentinel lymph-node biopsy on staging and treatment in patients with anal cancer
145. EP-1349: Long term results of a phase I-II study of moderate hypofractionated IGRT in prostate cancer
146. PO-0651: Five year outcome and soft tissue toxicity of breast cancer hypofractionated adjuvant radiotherapy
147. EP-1159: Hypofractionated adjuvant radiotherapy and concomitant trastuzumab for breast cancer: 5-year results
148. EP-1671: Calculation of the skin dose-of- the-day during Tomotherapy for head and neck cancer patients
149. OC-0222: GnRH receptor blockade reduces radiation-induced bladder toxicity: first evidence in a rat model
150. EP-1678: Are PET radiomic features robust enough with respect to tumor delineation uncertainties?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.